Educational Reference · Research-Use-Only
Epithalon: Mechanism, Research, and Regulatory Status
A research-grade overview of Epithalon — what it is, how it works at the molecular level, what published studies have shown, and answers to the questions researchers ask most.
Last reviewed 2026-07-28
What is Epithalon?
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, whose sequence was derived from the amino acid composition of Epithalamin, a bovine pineal gland extract. Distinguishing the two is essential when reading this literature: Epithalamin is a complex peptide extract, whereas Epithalon is a defined synthetic tetrapeptide, and the two have largely separate evidence bases. The most-cited proposed mechanism is telomere-related — addition of Epithalon to telomerase-negative human fetal fibroblast cultures was reported to induce expression of the telomerase catalytic subunit, enzymatic telomerase activity, and telomere elongation, with a follow-up reporting that treated fibroblasts underwent approximately ten additional passages beyond the control replicative limit.
A 2025 independent study reported dose-dependent telomere elongation in normal epithelial and fibroblast cells via hTERT and telomerase upregulation, and telomere extension in breast cancer cell lines via the Alternative Lengthening of Telomeres pathway, the ALT contribution being largely cancer-cell-specific; note that this paper carries a published correction. A second proposed mechanism involves direct interaction with nucleic acids, with reports that short regulatory peptides bind the DNA double helix and modulate gene transcription, though structural and biophysical characterization of this interaction remains limited. In rodent models, Epithalon has been reported to reduce chromosome aberration frequency in bone marrow cells and to downregulate HER-2/neu transcript expression in mammary tumors of transgenic mice.
Importantly, the frequently asserted claim that Epithalon restores melatonin secretion is not supported by direct measurement: an independent perifusion study found that Ala-Glu-Asp-Gly had no significant effect on melatonin secretion by pineal glands from either young or old rats, and did not modify stimulated melatonin release. The overall mechanistic picture remains poorly resolved.
Research highlights
What published peer-reviewed research and preclinical studies have established about Epithalon:
- 01In telomerase-negative human fetal fibroblast culture, Epithalon was reported to induce hTERT expression, telomerase enzymatic activity, and telomere elongation (Khavinson 2003).
- 02Treated human fetal pulmonary fibroblasts were reported to complete approximately ten additional passages beyond the control replicative limit (Khavinson 2004).
- 03An independent 2025 study reported dose-dependent telomere elongation in normal human cells via hTERT and telomerase upregulation, and ALT-mediated elongation largely specific to cancer cell lines; a correction to this article was subsequently published (Al-Dulaimi 2025).
- 04In female SHR mice, monthly administration did NOT influence mean life span; it increased the life span of the last 10% of survivors by 13.3% and maximum life span by 12.3%, and reduced bone marrow chromosome aberrations by 17.1% (Anisimov 2003).
- 05In HER-2/neu transgenic mice, treatment reduced cumulative tumor number and maximum tumor size and was associated with a 3.7-fold reduction in HER-2/neu transcript expression in mammary tumors (Anisimov 2002).
- 06A direct perifusion study by an independent group found Ala-Glu-Asp-Gly had no significant effect on melatonin secretion by rat pineal glands at any age or concentration tested, contradicting a commonly repeated claim (Djeridane 2003).
Frequently asked questions about Epithalon
What is the difference between Epithalon and Epithalamin?+
This distinction is essential when reading the literature. Epithalamin is a complex extract of bovine pineal tissue; Epithalon is a single defined synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from its amino acid composition. Most of the human observational literature concerns Epithalamin, while the telomerase and cell-culture work concerns Epithalon. Findings from one should not be attributed to the other.
What is the proposed mechanism?+
The most-studied hypothesis is induction of hTERT expression and telomerase activity with consequent telomere elongation, demonstrated in human cell culture. A secondary hypothesis involves direct peptide-DNA interaction modulating gene transcription, though this is not well characterized structurally. Recent review work notes that physicochemical and structural investigation of the peptide remains quite limited.
Does Epithalon affect melatonin?+
This is frequently claimed but is not supported by direct measurement. An independent perifusion study found that Ala-Glu-Asp-Gly produced no significant effect on melatonin secretion by pineal glands from young or old rats across the concentrations tested, and did not alter stimulated release. Melatonin-related claims should be treated as unsupported by the available direct evidence.
Are there human clinical trials?+
No. A ClinicalTrials.gov search returns no registered studies of the synthetic tetrapeptide. Human studies commonly cited in this context used Epithalamin, the bovine pineal extract, and were non-blinded, non-placebo-controlled, unregistered, and conducted by the institutions that developed the preparations.
How should the geroprotection literature be interpreted?+
With considerable caution. The rodent lifespan data are more limited than commonly represented — in the principal SHR mouse study, mean life span was not affected, with effects confined to maximum life span and the longest-lived decile. Most in vivo work originates from the institutions that developed the compound, replication outside those groups is sparse, and no registered human trials exist. Claims of anti-aging or life extension in humans are not supported by the published evidence.
What are the handling and stability considerations?+
As a short, highly polar lyophilized tetrapeptide it is hygroscopic; equilibrate to room temperature before opening. Reconstitute in sterile or bacteriostatic water with gentle swirling rather than vortexing, and aliquot to avoid repeated freeze-thaw cycles. Confirm identity and purity by HPLC and mass spectrometry on receipt.
References & sources
Every citation below was resolved against its primary source before publication — each PMID against the PubMed record and each DOI through doi.org. Follow any link to read the paper at the publisher rather than taking our summary on trust.
- [1]Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. PMID: 14631487 DOI: 10.1023/a:1026319711835
- [2]Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004. PMID: 15597092 DOI: 10.1007/s10517-004-0026-z
- [3]Anisimov VN, Khavinson VK, Popovich IG, et al.. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. PMID: 14618027 DOI: 10.1023/a:1026248413082
- [4]Anisimov VN, Khavinson VK, Provinciali M, et al.. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002. PMID: 12115542 DOI: 10.1002/ijc.10485
- [5]Djeridane Y, Khavinson VK, Anisimov VN, Touitou Y. Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. Journal of Endocrinological Investigation. 2003. PMID: 12809170 DOI: 10.1007/BF03345178
Where this data comes from
- —Citations & trial data: PubMed (NCBI, U.S. National Library of Medicine), Crossref and ClinicalTrials.gov.
- —Chemical identity: PubChem and UniProt. Where sources conflicted, the disputed value is omitted rather than guessed.
- —Regulatory status: U.S. FDA publications and, where applicable, the WADA Prohibited List. Compounding status changes frequently — verify against FDA directly before relying on it.
- —Purity, form and storage are handling and supplier conventions, not literature-derived values. Confirm against the lot-specific certificate of analysis.
Content last reviewed 2026-07-28. Compiled by Veridian Research from the primary literature. This page is an educational reference for laboratory researchers — it is not medical advice, and it describes no human use.
Regulatory status
Epithalon is not approved by the U.S. Food and Drug Administration for any indication and is not authorized for human use in the United States. FDA has placed Epitalon in Category 2 of the bulk drug substances nominated under sections 503A/503B of the FD&C Act — substances that may present significant safety risks — stating that compounded drugs containing epitalon may pose immunogenicity risk for certain routes of administration due to potential aggregation and peptide-related impurities. FDA's Pharmacy Compounding Advisory Committee reviewed Epitalon-related bulk drug substances in July 2026 for possible inclusion on the 503A Bulks List; advisory committee recommendations are non-binding and this status is live and may change, so verify against FDA's current published position rather than any secondary source. Unlike Semax and Selank, Epithalon is not a registered medicine in the Russian Federation; the related pineal extract preparation Epithalamin is a separate product and should not be conflated with the synthetic tetrapeptide. Supplied strictly for in vitro and non-human laboratory research; not for human or veterinary use.
Research-Use-Only Material
Specifications and certificate of analysis
Epithalon is stocked as a research reagent. Analytical documentation — identity, purity and the lot-specific certificate of analysis — is published on the product record.
View specifications & COA →